We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Bone Health and Denosumab Discontinuation in Oncology Populations.
- Authors
Cheung, Yee-Ming Melody; Morgans, Alicia; Hamnvik, Ole-Petter Riksfjord
- Abstract
The article discusses the evidence surrounding the efficacy and safety of various bone health agents in mitigating the rebound phenomenon in cancer populations. Topics include the approval of antiresorptive agents for the management of metastatic bone disease in patients with solid tumors, common adverse effects for zoledronate, and clinical scenarios where discontinuation of denosumab should be considered.
- Subjects
THERAPEUTIC use of monoclonal antibodies; RISEDRONATE; BONES; ALENDRONATE; CANCER patients; ZOLEDRONIC acid; TREATMENT effectiveness; TERMINATION of treatment; DECISION making in clinical medicine; VERTEBRAL fractures
- Publication
Oncologist, 2022, Vol 27, Issue 12, p998
- ISSN
1083-7159
- Publication type
Article
- DOI
10.1093/oncolo/oyac213